Drug Profile
LGD 4665
Alternative Names: 2285921; GSK-2285921; GSK-5291Latest Information Update: 16 Aug 2023
Price :
$50
*
At a glance
- Originator Ligand Pharmaceuticals
- Developer GSK; Ligand Pharmaceuticals
- Class Small molecules
- Mechanism of Action Thrombopoietin stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Idiopathic thrombocytopenic purpura
Most Recent Events
- 02 Sep 2015 No recent reports on development identified - Phase-II for Idiopathic thrombocytopenic purpura in USA (PO)
- 18 Dec 2008 LGD 4665 licensed to GlaxoSmithKline worldwide
- 09 Dec 2008 Interim efficacy & adverse events data from a phase IIa trial in Immune thrombocytopenic purpura presented at the presented at the 50th Annual Meeting and Exposition of the American Society of Hematology (ASH-2008) ,